Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | STK3 | Q13188 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748407 | 0.85 | ROCK2 (0.50) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL14748384 | 0.85 | ROCK2 (0.49) | ROCK2ROCK1PIK3CA | |
| SCHEMBL1819487 | 0.84 | PIK3CA (0.69) | ROCK2ROCK1PIK3CA | |
| SCHEMBL14748368 | 0.76 | ROCK1 (0.44) | ROCK2ROCK1 | |
| SCHEMBL2468942 | 0.73 | PIK3CA (0.67) | ROCK2ROCK1PIK3CA | |
| SCHEMBL1822964 | 0.73 | ROCK2 (0.47) | ROCK2ROCK1PIK3CACLK2BLK | |
| SCHEMBL1820245 | 0.70 | PIK3CA (0.52) | ROCK2ROCK1PIK3CA | |
| SCHEMBL30743051 | 0.69 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877829 | 0.69 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL18038217 | 0.69 | ROCK1 (1.00) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |